WHY IT MATTERS: If India’s human trials produce strong safety and efficacy data, it could accelerate regulatory acceptance of medicinal cannabis across South and Southeast Asia, potentially expanding patient access in regions where options are currently very limited. CLINICAL OVERVIEW: India’s launch of human clinical trials for medicinal cannabis represents a significant regulatory and scientific shift for a country with historically strict drug policies. These trials will generate controlled safety and efficacy data across specific medical conditions, helping to establish evidence-based frameworks for potential therapeutic use.